Medimaps Group and Radiobotics have announced a strategic merger agreement to create a unified, AI-driven musculoskeletal (MSK) imaging platform. The transaction, pending Danish foreign direct investment approval and customary closing conditions, combines Medimaps’ expertise in bone microarchitecture analysis with Radiobotics’ AI-powered fracture detection tools. Together, the companies aim to accelerate global adoption of AI-enabled MSK imaging across X-ray and DXA modalities.
The merged entity will offer a comprehensive portfolio spanning automated fracture detection, opportunistic bone fragility assessment, and long-term fracture risk prediction. Medimaps’ solutions—including TBS Osteo™ and TBS Reveal™—will integrate with Radiobotics’ RBfracture™ platform, with all tools designed to embed seamlessly into existing radiology workflows via PACS integration. The companies describe the partnership as the creation of the first end-to-end MSK AI ecosystem, transforming routine imaging into both diagnostic and preventive tools.
The combined organization plans to expand its reach across 90 markets worldwide, including the United States, serving hospitals, clinics, and imaging centers. Leadership from both companies will remain in place to ensure continuity and preserve specialized MSK expertise. Executives from both sides emphasized that the merger strengthens efforts to address the growing clinical and economic burden of fractures and osteoporosis—conditions that generate billions in annual healthcare costs and place sustained pressure on emergency departments and care pathways.
By integrating fracture detection with predictive bone health analytics, the new entity aims to shift care from reactive treatment toward proactive prevention. Financial terms of the transaction were not disclosed.
Click here to read the original news story.